MedPath

DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer

Recruiting
Conditions
Pancreatic Cancer
Registration Number
NCT05604573
Lead Sponsor
Seoul National University Hospital
Brief Summary

Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins
  • Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule
  • Among patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group
Exclusion Criteria
  • Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form
  • If a laboratory test is impossible due to a qualitative problem with the collected blood sample
  • Where the collected tissue does not contain tissue of the desired malignant or benign disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
correlation of genetic mutationthe day of study enrollment (baseline)

concordance of genetic mutation between tissue and blood of treatment-naive status

detection sensitivity of genetic mutation by mmADPSthe day of study enrollment (baseline)

detection sensitivity of genetic mutation by mmADPS

Secondary Outcome Measures
NameTimeMethod
correlation of genetic mutation and prognosisthrough study completion, an average of 1 year

correlation of genetic mutation and prognosis

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Sang Hyub Lee, MD PhD
Principal Investigator
Jin Ho Choi, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.